Ensysce Biosciences (ENSC) said Wednesday it has received a notice of allowance for PF9001, a medication for treating opioid use disorder, from the US Patent and Trademark Office.

Data showed that the medication reduced the potential for cardiotoxicity and could potentially deliver a prolonged and predictable effect on daily dosing, the biotechnology company said.

Shares were over 125% higher in recent premarket activity.